A New Revolutionary Nerve-Sensing Technology That Every Investor Should Research

Breakthrough nerve-sensing technology has the potential to help treat a wide range of disorders ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ A Message from Autonomix   |   Unsubscribe For many, pain can be a constant in life, which is why painkillers are such a huge market – despite typically being a temporary (and sometimes dangerous) "band-aid" solution. Autonomix has a better idea: Target pain at its source in the nervous system. Alongside pain management, their breakthrough nerve-sensing technology has the potential to help treat a wide range of disorders including high blood pressure and digestive issues. It's all with one tiny microchip that's intended to target nerve signals at an accuracy never seen before. The team has 100+ patents issued and pending, and with an estimated total of $100B+ in markets to address, we believe it's a unique opportunity for investors. See how you can invest Autonomix before their planned NASDAQ listing.

This message is a paid advertisement sent on behalf of Autonomix, a third-party advertiser of MarketBeat. Why did I receive this email?     This message is a paid advertisement for Autonomix from Autonomix and Strikepoint. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $15,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Autonomix or Strikepoint. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Autonomix on Strikepoint' website for additional information about the relationship between Strikepoint and Autonomix.     If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.   © 2006-2023 American Consumer News, LLC dba MarketBeat. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.   Today's Bonus Content: Buy this AI Stock Before Elon's Announcement